MedPath

Elucidation of individual differences in blood concentration of posaconazole in patients with blood diseases and analysis of the relationship with clinical laboratory test values

Not Applicable
Recruiting
Conditions
Blood dyscrasia
Registration Number
JPRN-UMIN000045046
Lead Sponsor
Hamamatsu University School of Medicine Department of Hospital Pharmacy
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
120
Inclusion Criteria

Not provided

Exclusion Criteria

1) Those who the doctor deems inappropriate 2) Those who did not consent to participate in this study 3) Patients with severe liver or renal dysfunction 4) Patients taking azole antifungal drugs other than PSCZ

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1 Blood concentration (total concentration, free form concentration) of PSCZ and its metabolites, free form fraction 2 Factors that change blood dynamic parameters (clinical test values, diseases, combination drugs, inflammatory markers, hepatic / renal function marker concentrations, pharmacokinetic-related biomarker concentrations) 3 Gene polymorphism of drug-metabolizing enzymes (CYP3A4, CYP3A5, UGT1A), drug transport carriers (ABCB1, OATP1B), blood microRNA concentration 4 Blood concentration of concomitant drugs (tacrolimus, cyclosporine, letermovir) (only when used in combination)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath